Free Newsletter
Biogen reports 11th PML case for Tysabri
Free newsletter via e-mail
Tools
An eleventh patient taking Biogen Idec and Elan's multiple sclerosis drug Tysabri has developed a potentially deadly brain infection, the company announced in its weekly update on PML cases. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: